Breakthrough Drug Mavacamten Shows Major Benefits for Heart Disease Patients

A new study in Circulation: Genomic and Precision Medicine has confirmed the effectiveness of mavacamten in treating obstructive hypertrophic cardiomyopathy (oHCM). The drug, marketed as Camzyos, showed significant benefits when used alone in patients with this heart condition. Researchers highlighted its potential to transform care for those affected by oHCM.

The study found that mavacamten, when used as a standalone treatment, led to marked improvements in patients. On average, the left ventricular outflow tract gradient—a key measure of obstruction—fell by 35 to 59 mmHg. By the end of the treatment period, most participants no longer met the clinical threshold for obstruction.

Functional improvements were also notable. Around 60% of patients saw their condition improve by at least one NYHA functional class, indicating better mobility and reduced symptoms. The drug's developer, MyoKardia, was acquired by Bristol Myers Squibb in 2020 for $13.1 billion, signalling strong confidence in its potential.

Bristol Myers Squibb is now expanding mavacamten's use. The company has launched trials to assess its effectiveness in adolescents with symptomatic oHCM and is conducting long-term studies in adults. These efforts aim to determine whether the drug's benefits persist over extended periods.

The findings could strengthen Bristol Myers Squibb's position in the global market for specialised cardiac treatments. However, the study did not specify the total number of oHCM patients involved in this latest research.

Mavacamten has demonstrated clear benefits for oHCM patients, reducing obstruction and improving daily function. Long-term studies will now assess whether these results hold over time, which could influence its broader adoption. The drug's ongoing trials in younger patients may further expand its reach in treating this condition.